Research ArticleArticle
Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study
Yoshiaki Furuya and Masataka Kuwana
The Journal of Rheumatology September 2011, jrheum.110499; DOI: https://doi.org/10.3899/jrheum.110499
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study
Yoshiaki Furuya, Masataka Kuwana
The Journal of Rheumatology Sep 2011, jrheum.110499; DOI: 10.3899/jrheum.110499